5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study

BACKGROUND: Sunitinib is an oral inhibitor of tyrosine kinase receptors implicated in tumor proliferation, angiogenesis, and metastasis. In this randomized, multicenter, open-label Phase IIb study, sunitinib plus mFOLFOX6 (oxaliplatin plus leucovorin plus 5-fluorouracil) was compared with bevacizuma...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Manag Res
Hlavní autoři: Hecht, J Randolph, Mitchell, Edith P, Yoshino, Takayuki, Welslau, Manfred, Lin, Xun, Chow Maneval, Edna, Paolini, Jolanda, Lechuga, Maria Jose, Kretzschmar, Albrecht
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4474399/
https://ncbi.nlm.nih.gov/pubmed/26109878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S61408
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky